Huntington’s Disease – Opportunity Assessment and Forecast to 2030

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Huntington’s disease (HD) is a rare, autosomal-dominant, neurodegenerative disorder, characterized by impaired motor control, cognitive dysfunction, behavioral changes, and mood disorders. Depending upon the age of disease onset, HD can be classified into two forms: the more traditional adult-onset HD and the less prevalent juvenile-onset HD (JHD), also known as the Westphal variant of HD.

Approved treatments for HD across US, UK, and Germany are extremely limited, consisting of only two symptomatic treatments, tetrabenazine and deutetrabenazine, which are approved for the treatment of HD-associated chorea. Other treatment options contributing to the HD market are off-label off-patent symptomatic drugs including antipsychotics, antidepressants, benzodiazepines, anticonvulsants, antiparkinsonian drugs, and botulinum toxin. To date, no disease-modifying drugs (DMDs) are available for the treatment of HD, and the current treatments are used in an attempt to alleviate the symptoms associated with this progressive disease.

Neurocrine’s Ingrezza (valbenazine) is expected to launch in the US in 2023, and it will directly compete with Teva’s Austedo (deutertabenazine). Huntexil (pridopidine) is expected to launch in 2025 in the US and in 2026 in Germany and the UK. As it will target the non-choreic symptoms, it will likely be prescribed on top of other treatments, or it will replace some off-label drug use.

Key Questions Answered

– What are the key HD treatments in 2020?

– When will the late stage pipeline products launch, and how will it affect drug sales and the overall HD market in the 3MM?

– Which unmet needs will remain unaddressed in the forecast period and what opportunities remain for pharmaceutical companies?


Overview of Huntington's Disease, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.

Topline Huntington's Disease market revenue from 2020-2030. Annual cost of treatment and major pipeline product sales in this forecast period are included.

Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting Huntington's Disease treatment sales in the 3MM.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.

Analysis of the current and future market competition in the global Huntington's Disease market. Insightful review of the key industry drivers, constraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

During the 10-year forecast period, there are two major pipeline products on track to launch, driving a forecast growth in the 3MM from $251.7m in 2020 to $917.7m in 2030.

Neurocrine’s Ingrezza (valbenazine) is expected to launch in the US in 2023, and it will directly compete with Teva’s Austedo (deutertabenazine).

Huntexil is expected to launch in 2025 in the US and in 2026 in Germany and the UK. As it will target the non-choreic symptoms, it will likely be prescribed on top of other treatments, or it will replace some off-label drug use.

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global Huntington's Disease market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Huntington's Disease market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Bausch Health
Anima Biotech
Wave Life Sciences
Prilenia Therapeutics
Neurocrine Biosciences

Table of Contents

1 Executive Summary

2 Disease Overview

2.1 Definition of Huntington's Disease

2.2 HD SWOT Analysis

2.3 Classification of HD

3 Epidemiology

3.1 Diagnosed Prevalent Cases of HD, 2020-2030

3.2 Diagnosed Prevalent Cases of HD by Specific Type, 2020

3.3 Sources and Methodology

3.4 Diagnosis of HD – Treatable Population

4 Current Treatment Options

4.1 Treatment Paradigm

4.2 Marketed Products

4.3 Product Profile: Bausch Health’s Xenazine (tetrabenazine)

4.4 Product Profile: Teva’s Austedo (deutetrabenazine)

4.5 Product Profile: Antipsychotics

4.6 Product Profile: Antidepressants

4.7 Product Profile: Benzodiazepines

4.8 Product Profile: Anticonvulsants

4.9 Product Profile: Antiparkinsonian drugs

4.10 Product Profile: Botulinum Toxin Type A

5 Unmet Needs and Opportunities

5.1 Unmet Needs in HD

6 R&D Strategies

6.1 Trends in Clinical Trial Design in HD

6.2 Trends in Deal-Making in HD

7 Pipeline Assessment

7.1 Huntington's Disease: Pipeline Overview

7.2 Product Profile: Prilenia Therapeutics’ Huntexil (Pridopidine)

7.3 Product Profile: Neurocrine Biosciences’ Ingrezza (Valbenazine)

8 Market Outlook

8.1 Huntington's Disease Market Growth

8.2 Huntington's Disease Market Forecast

8.3 Market Drivers and Barriers

9 Appendix

9.1 Primary Research: KOL Information

9.2 About the Authors

10 Contact Us

Frequently asked questions

Huntington’s Disease – Opportunity Assessment and Forecast to 2030 standard reports
Currency USD

Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Huntington’s Disease – Opportunity Assessment and Forecast to 2030 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Huntington’s Disease – Opportunity Assessment and Forecast to 2030 in real time.

  • Access a live Huntington’s Disease – Opportunity Assessment and Forecast to 2030 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.